{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:10:28Z","timestamp":1764349828207},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T00:00:00Z","timestamp":1134604800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Oral isotretinoin (OI) is currently the gold standard in the treatment of moderately severe to severe acne vulgaris. Approximately 50\u201385% of patients achieve permanent cure with one course based on 1.0\u20132.0\u00a0mg\/kg\/body weight. It has been shown that a dosage of less than 1\u00a0mg\/kg\/body weight predisposed to noncure and required a second course for a permanent cure.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> Purpose of this study was to describe the profile of acne patients in the Philippines requiring a second course of OI.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Charts of acne vulgaris patients given OI in a private dermatology clinic (SSJ) over a period of 10\u00a0years were reviewed and analyzed. All patients were given a total dose of 1\u00a0mg\/kg\/body weight (cumulative total dose of 120\u00a0mg\/kg\/body weight).<\/jats:p><jats:p><jats:bold>Result\u2002<\/jats:bold> Of 240 patients taking OI included in the study, 193 completed the entire course. One hundred and 43 (59.6%) were cured after one course and required no further therapy (control group: CG), 42 (17.5%) experienced relapse and were treated with topical therapy, and eight (3.3%) relapsed and required oral antibiotic plus topical therapy. Only 47 patients (19.6%) required a second course of OI therapy (study group: SG). There was no difference between the two groups in age, sex, severity, and location of lesions. Two factors were found to be of statistically significant difference: Total dose actually taken with 103.5\u00a0mg\/kg\/body weight for the SG vs. 118.55\u00a0mg\/kg\/body weight for the CG. Median duration of treatment was 6.7\u00a0months for the SG vs. 7.41\u00a0months for the CG, respectively.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The profile of acne patients in the Philippines requiring a second course of OI is seen in those taking a mean cumulative dose (actual total dose) less than 120\u00a0mg\/kg\/body weight, with a mean actual duration of 6.7\u00a0months.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2005.02284.x","type":"journal-article","created":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T16:39:28Z","timestamp":1134664768000},"page":"999-1001","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Profile of acne patients in the Philippines requiring a second course of oral isotretinoin"],"prefix":"10.1111","volume":"44","author":[{"given":"Indra","family":"Haryati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia S.","family":"Jacinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3810\/pgm.1997.08.287","article-title":"Dispelling myths about acne","volume":"102","author":"Landaw K","year":"1997","journal-title":"Postgrad Med"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113717"},{"issue":"2","key":"e_1_2_6_4_2","first-page":"28","article-title":"Accutane\u00ae\u2013 exposed pregnancies \u2013 California 1999","volume":"49","author":"CDC","year":"2000","journal-title":"MMWR"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120529"},{"key":"e_1_2_6_6_2","first-page":"1823","article-title":"Use of systemic agents in the treatment of acne vulgaris","volume":"62","author":"Johnson BA","year":"2000","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246134"},{"key":"e_1_2_6_8_2","unstructured":"Isotretinoin. Patient Information Handout:http:\/\/www.geocities.com\/Athens\/Ithaca\/3427\/ptinfo.htm."},{"key":"e_1_2_6_9_2","unstructured":"Roaccutane Information.Info from Dr. Kaminer:http:\/\/www.geocities.com\/beat_acne\/roaccutane.html."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80252-6"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb11849.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb11850.x"},{"key":"e_1_2_6_13_2","unstructured":"PeckGL.Retinoids. In:FreedbergL EisenA WolffK et\u00a0al. ed.Fitzpatrick's Dermatology in General Medicine 5th edn.2000;2810\u20132812."},{"key":"e_1_2_6_14_2","unstructured":"Health Drug Index: Accutane Copyright @ 2002 Thomson Health\u2010Care:http:\/\/www.CTCL.consult.com."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000248702"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","unstructured":"WhiteGM ChenW et al.Recurrence rate after the first course of isotretinoin archives of dermatology.1998; 134:376\u2013378.","DOI":"10.1001\/archderm.134.3.376"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.115965"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000248869"},{"key":"e_1_2_6_19_2","first-page":"1","article-title":"AAD consensus conference on isotretinoin yields statement","volume":"12","author":"Helwick C","year":"2002","journal-title":"Dermatology World"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70104-A"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018130"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2005.02284.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2005.02284.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:06:11Z","timestamp":1695859571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2005.02284.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1365-4632.2005.02284.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2005.02284.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"2005-12-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}